Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
- CAS Registry Number
- 202138-50-9
- Molecular formula
- C23H34N5O14P
- Molecular weight
- 635.5 g/mol
- Drug class
- Acyclic nucleotide phosphonate prodrugantiretroviral reverse-transcriptase inhibitor precursor
- Mechanism of action
- Tenofovir disoproxil is a prodrug that is hydrolysed to tenofovir and subsequently phosphorylated intracellularly to tenofovir diphosphate. Tenofovir diphosphate competitively inhibits HIV reverse transcriptase and HBV DNA polymerase and causes DNA-chain termination. Fumarate is the salt component; the disoproxil moiety is the prodrug.
- Indications / reported uses
- Treatment of HIV-1 infection in combination with other antiretroviral agents
- Treatment of chronic hepatitis B in adults and adolescents where authorised; use requires current product-specific eligibility, renal assessment and monitoring
Identification source: PubChem record (CID 6398764). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.